Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xorlo
- Development stage
- Unknown
- Lead developer
- XORTX Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
XORLO is a proprietary oral formulation of oxypurinol developed by XORTX Therapeutics. Oxypurinol is a purine-based xanthine oxidase inhibitor (XOI) that reduces uric acid production by inhibiting the enzyme xanthine oxidase. XORLO has been specifically engineered to improve the bioavailability and systemic exposure of oxypurinol compared to non-formulated versions. The drug is being developed for two main indications: - Autosomal Dominant Polycystic Kidney Disease (ADPKD), where it aims to slow kidney function decline by reducing uric acid–mediated injury. - Gout, particularly in patients intolerant to allopurinol. Clinical studies have shown that XORLO achieves higher systemic exposure and improved pharmacokinetics with minimal adverse effects. The product has received orphan drug designation for ADPKD and is advancing through late-stage clinical development for both ADPKD and gout[1][2][5][7].
- Brand names
- XORLO
- Other names
- oxypurinol proprietary formulationoxypurinol - XORTX
02
Targets
XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on xorlo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xorlo.